Author presents a long thesis on Iovance Biotherapeutics (IOVA), citing a heavily shorted setup, upcoming late-Feb/early-March revenue results and product ramp updates, and recent short-covering price action.
IOVA — LONG The author claims IOVA is a severely undervalued FDA-approved biotech whose product is ramping and whose shares have been shorted into oblivion, with about 30% short interest and limited available shares to short. They expect near-term catalysts in late February/early March, including revenue results and product-ramp updates, to force short covering and drive the stock higher from around $2.69 after recent liquidations and sharp volume spikes. The author states they are long calls.
I believe as of right now it has 30% short interest, approximately 130 million shares with a 8-9 days to exit on Volume, maybe slightly less after the last 3 days of forced exits.
This Reddit post, published January 22, 2026, features u/Glad-River7299 discussing IOVA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Glad-River7299 · Tickers: IOVA